logo
Aton Reports Further Diamond Drilling Results From Abu Marawat, Including 8.52 g/t Gold and 88.7 g/t Silver Over 15.4 Metres, and 6.06 g/t Gold and 59.6 g/t Silver Over 17.3 Metres

Aton Reports Further Diamond Drilling Results From Abu Marawat, Including 8.52 g/t Gold and 88.7 g/t Silver Over 15.4 Metres, and 6.06 g/t Gold and 59.6 g/t Silver Over 17.3 Metres

VANCOUVER, BC / ACCESS Newswire / May 20, 2025 / Aton Resources Inc. (TSXV:AAN) ('Aton' or the 'Company') updates investors on the results of its ongoing diamond drilling programme at the Abu Marawat deposit ('Abu Marawat'), located within the retained exploration areas of the Company's Abu Marawat Concession (the 'Concession') in the Eastern Desert of Egypt.
Highlights:
'This latest tranche of results from the horizontal diamond drilling programme at Abu Marawat is very pleasing, and is indicating the presence of a significant near-surface core of high grade mineralisation on the CVZ' said Tonno Vahk, CEO. 'We are also seeing some nice looking mineralisation in the ongoing RC programme at Semna, and we expect to be able to release the first results from this programme in the coming weeks. The programme at Abu Marawat is approaching the finish line, and we are also now doing some additional drilling there for a metallurgical testwork programme. The identification and delineation of high grade mineralisation near to surface at both Abu Marawat and Semna is very positive as Aton looks to the long term development of multiple mining operations at the Abu Marawat Concession. Work on the Hamama West PFS and ESIA is continuing steadily, with the ongoing establishment of the environmental baseline, and we are planning to start the next phase of hydro drilling at Hamama in the coming weeks, as we seek to establish a viable groundwater supply for the mining projects.'
Abu Marawat gold-silver-copper-zinc deposit
The Abu Marawat gold-silver-copper-zinc deposit is located approximately 35km northeast of the Hamama West deposit and 10km north-northeast of the Semna gold mine project, and is accessed via a well maintained desert track from the Qena-Safaga highway, approximately 25km to the north (Figure 1). On March 1, 2012 Aton Resources, when formerly named Alexander Nubia International Inc, announced a maiden Inferred Mineral Resource at Abu Marawat, prepared by Roscoe Postle Associates Inc., in compliance with the requirements set out in Canada's National Instrument 43‐101. The resource was subsequently restated in an updated Technical Report without amendment (see news release dated January 24, 2017), and which is available online at Aton's website at https://atonresources.com/investors/reports-and-presentations. This Inferred Mineral Resource was based on 98 diamond drill holes totalling 19,573 metres. 19 of these holes were drilled by a former property owner, Minex Minerals Egypt, a wholly owned subsidiary of Greenwich Resources Plc during the late 1980's, and the remainder were drilled by Aton in 2011. The Inferred Mineral Resource comprises 2.9 million tonnes at an average grade of 1.75 g/t Au, 29.3 g/t Ag, 0.77% Cu and 1.15% Zn, containing 162 thousand ounces of gold, 2.7 million ounces of silver, 49 million lbs of copper, and 73 million lbs of zinc, and was based on net smelter return ('NSR') cut‐off grades.
Figure 1: Geology plan of the Abu Marawat Concession, showing the location of the Abu Marawat deposit
The polymetallic mineralisation at Abu Marawat is interpreted as being mesothermal in origin, and occurs in a series of discrete and roughly parallel N-S to NNW-SSE trending veins and structures, of which the Fin Vein and the CVZ are the most significant, hosted within a sequence of intensely hydrothermally altered, felsic metavolcanic rocks (Figure 2). The Fin Vein and the CVZ are about 50-100m apart and have been traced for at least 800m in surface outcrop and drill holes. Aton's previous drilling has demonstrated that these structures extend to at least 200m in depth. The bulk of the Inferred Mineral Resource at the Abu Marawat deposit encompasses parts of the CVZ and the Fin Vein, but there are also other subparallel mineralised veins to the east and to the west of these structures, such as the J Vein, the JVZ structure, and the Valley Vein zone (Figure 2).
The mineralisation at Abu Marawat comprises a series of steep to near vertical finely brecciated quartz-carbonate-sulphide 'veins'. At surface the Fin Vein and CVZ are expressed by quartz-rich gossans, and all the larger structures display development of intense wallrock alteration in outcrop. Several of the veins, notably the CVZ, were mined at surface in ancient times, apparently primarily for copper. The mineralised system at Abu Marawat currently remains open both laterally and at depth.
Further to the north, the Abu Marawat deposit appears to be truncated by a large WNW-ESE trending fault postulated to run beneath wadi sediments. To the east a prominent ridge composed of altered ultramafic rocks is thought to represent a significant geological terrane boundary (Figure 2).
Figure 2: Geology plan of the Abu Marawat area, showing the location of pre-2024 Aton drill holes
Figure 3: Geology and drill hole collar plan of holes targeting the CVZ and Fin Vein structures, AMD-146 to AMD-164
Abu Marawat diamond drilling programme
The current diamond drill programme started in June 2024, and to date 95 diamond drill holes (holes AMD-101 to AMD-195) have been completed, for a total of 7,917.2 metres. All the holes have been drilled horizontally or at shallow angles to test previously undrilled near-surface mineralisation.
Assay results are now available for a further 21 holes, AMD-146 to AMD-166, and the collar details of these holes are provided in Appendix A. The holes were predominantly designed to test the CVZ, near to the surface, with the drilling on west-southwesterly azimuths. Some holes were extended to intersect the Fin Vein further to the west. The drilling was focussed on the central area of the Abu Marawat deposit (Figure 2).
Holes AMD-165 and AMD-166 were also drilled on west-south westerly azimuths towards the southern end of the CVZ.
Discussion of results
All intersection details from the currently reporting holes AMD-146 to AMD-166 are provided in Appendix B, with selected intersections shown below in Table 1.
Table 1: Selected intersections from the Abu Marawat diamond drilling programme, AMD-146 to AMD-166
This latest tranche of drill holes again returned significant polymetallic mineralised intersections from the CVZ, in some cases carrying notably high grades of gold, silver and also copper over consistent widths. These intersections including 8.52 g/t Au, 88.7 g/t Ag, 9.50 g/t gold equivalent ('AuEq', calculated using Au and Ag only, with a Au:Ag ratio of 90), 2.15% Cu and 0.59% Zn over a 15.40m interval, from 23.50m downhole depth (hole AMD-151); 6.06 g/t Au, 59.6 g/t Ag, 6.72 g/t AuEq, 1.02% Cu and 1.24% Zn over a 17.30m interval, from 32.80m downhole depth (hole AMD-146); and 4.14 g/t Au, 40.7 g/t Ag, 4.59 g/t AuEq, 0.85% Cu and 0.17% Zn over a 13.90m interval, from 13.30m downhole depth (hole AMD-149). These intersection widths effectively reflect the true width of the mineralised CVZ structure. Please refer to the news release dated March 11, 2025 for further details about the CVZ mineralisation.
Hole AMD-165, drilled at the southern outcropping extent of the CVZ also intersected a wide zone of mineralisation on the CVZ (0.69 g/t Au, 19.4 g/t Ag, 0.90 g/t AuEq and 0.21% Cu, over a 23.90m interval from 33.10m downhole depth), albeit at a lower grade. This phase of the drilling has indicated a continuous body of near-surface mineralisation in excess of 250m strike length in the central part of the CVZ, with notably high grades of gold, silver, copper and also zinc, particularly in its central core, although the grades diminish towards the southern and northern ends of the structure. A further phase of reverse circulation percussion ('RC') drilling is planned to test the deeper parts of the CVZ and to infill and confirm the previous diamond drilling carried out by Aton during 2011 and Minex during the 1980's.
Activity Update
Sampling and analytical procedures
The Abu Marawat diamond drill holes were drilled at a combination of either HQ3 size (61.1mm diameter) and/or PQ3 size (83mm diameter). Core was loaded into metal core boxes by the drill crew under supervision of Aton geologists. The core was metre marked onsite at the Abu Marawat camp, with basic geotechnical measurements (total core recovery, solid core recovery, and rock quality designation) undertaken by Aton geologists, as well as specific gravity measurements. It was also photographed in both wet and dry states at Abu Marawat. The core was then carefully packed and transported to the Rodruin exploration camp, where it was geologically logged by senior Aton geologists, and marked up for cutting and sampling at the Rodruin core farm. Samples were typically selected over nominal 1m intervals, but as determined by the logged lithologies. The core was half-cut by Aton staff at the onsite Rodruin sample preparation facility. After the core had been cut, the relevant cut intervals were then photographed again.
The split half-core samples were collected and bagged up in cloth bags, weighed and crushed to -4mm onsite, and split to a nominal c. 500-1,000g sample size. The coarse crushed reject samples are retained onsite at the Rodruin sample preparation facility.
QAQC samples were inserted into the sample runs at a rate of approximately 1 certified reference material (or 'standard' sample) every 30 samples, 1 blank sample every 15 samples, and 1 duplicate split sample every 15 samples.
The dried, crushed and split samples were shipped to ALS Minerals sample preparation laboratory at Marsa Alam, Egypt, where they were pulverised to a size fraction of better than 85% passing 75 microns. From this pulverised material a further sub-sample was split off with a nominal c. 100g size, which was shipped on to ALS Minerals at Rosia Montana, Romania for geochemical analysis. The reject pulp material was returned to the sample preparation facility at Rodruin, where it is also retained onsite
The samples were analysed for gold by fire assay (30g charge) with an atomic absorption spectroscopy ('AAS') finish (analytical code Au-AA23). Any high grade gold samples (>10 g/t Au) were re-analysed using analytical code Au-GRA21 (also fire assay, with a gravimetric finish).
Samples were also analysed for silver, copper, lead and zinc using an aqua regia digest followed by an AAS finish (analytical code AA45). Any high grade silver and base metal samples (Ag >100 g/t, and Cu, Pb or Zn >10,000ppm or >1%) were re-analysed using the ore grade technique AA46 (also an aqua regia digest followed by an AAS finish).
About Aton Resources Inc.
Aton Resources Inc. (TSXV:AAN) is focused on its 100% owned Abu Marawat Concession ('the Concession'), located in Egypt's Arabian-Nubian Shield, approximately 200 km north of AngloGold Ashanti's world-class Sukari gold mine. Aton has identified numerous gold and base metal exploration targets at the Concession, including the Hamama deposit in the west, the Abu Marawat deposit in the northeast, and the Rodruin deposit in the south of the Concession. Two historic British gold mines are also located on the Concession at Semna and Sir Bakis. Aton has identified several distinct geological trends within the Concession, which display potential for the development of a variety of styles of precious and base metal mineralisation. The Abu Marawat exploitation lease is 57.66 km2 in size, covering the Hamama West and Rodruin mineral deposits, and was established In January 2024 and is valid for an initial period of 20 years. The Concession also includes an additional 255.0 km2 of exploration areas, retained for a further period of 4 years from January 2024. The Concession is located in an area of excellent infrastructure; a four-lane highway, a 220kV power line, and a water pipeline are in close proximity, as are the international airports at Hurghada and Luxor.
Qualified person
The technical information contained in this News Release was prepared by Javier Orduña BSc (hons), MSc, MCSM, DIC, MAIG, SEG(M), Chief Geologist of Aton Resources Inc. Mr. Orduña is a qualified person (QP) under National Instrument 43-101 Standards of Disclosure for Mineral Projects.
For further information regarding Aton Resources Inc., please visit us at www.atonresources.com or contact:
TONNO VAHK
Chief Executive Officer
Tel: +1 604 318 0390
Email: [email protected]
Note Regarding Forward-Looking Statements
Some of the statements contained in this release are forward-looking statements. Since forward-looking statements address future events and conditions; by their very nature they involve inherent risks and uncertainties. Actual results in each case could differ materially from those currently anticipated in such statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Appendix A -Abu Marawat diamond drill hole collar details, holes AMD-146 to AMD-166
Appendix B - Abu Marawat significant intersections, holes AMD-146 to AMD-166
SOURCE: Aton Resources, Inc.
press release
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

TSX Penny Stocks To Watch In July 2025
TSX Penny Stocks To Watch In July 2025

Yahoo

time6 hours ago

  • Yahoo

TSX Penny Stocks To Watch In July 2025

Despite the challenges posed by rising tariff rates, Canadian markets have shown resilience, with inflation and economic data remaining stable. For investors exploring beyond well-known names, penny stocks—often representing smaller or newer companies—continue to hold potential value despite the term's outdated feel. By focusing on those with robust financials and a clear growth trajectory, investors may uncover opportunities that balance stability with potential upside in the ever-evolving market landscape. Top 10 Penny Stocks In Canada Name Share Price Market Cap Financial Health Rating Westbridge Renewable Energy (TSXV:WEB) CA$0.66 CA$67.77M ★★★★★★ Fintech Select (TSXV:FTEC) CA$0.03 CA$2M ★★★★★★ Foraco International (TSX:FAR) CA$1.76 CA$177.53M ★★★★★☆ Findev (TSXV:FDI) CA$0.42 CA$12.18M ★★★★★★ Thor Explorations (TSXV:THX) CA$0.775 CA$518.93M ★★★★★★ Pulse Seismic (TSX:PSD) CA$3.54 CA$174.09M ★★★★★★ Avino Silver & Gold Mines (TSX:ASM) CA$4.94 CA$698.44M ★★★★★★ ACT Energy Technologies (TSX:ACX) CA$4.84 CA$158.9M ★★★★★☆ Hemisphere Energy (TSXV:HME) CA$1.94 CA$185.15M ★★★★★★ McChip Resources (TSXV:MCS) CA$1.65 CA$10.28M ★★★★★★ Click here to see the full list of 454 stocks from our TSX Penny Stocks screener. Here's a peek at a few of the choices from the screener. BeWhere Holdings Simply Wall St Financial Health Rating: ★★★★★☆ Overview: BeWhere Holdings Inc. is an industrial Internet of Things (IIoT) solutions company that designs, manufactures, and sells hardware with sensors and software applications for tracking real-time information on equipment, tools, and inventory both in-transit and at facilities, with a market cap of CA$70.91 million. Operations: The company generates revenue primarily from its Software & Programming segment, amounting to CA$18.25 million. Market Cap: CA$70.91M BeWhere Holdings Inc., with a market cap of CA$70.91 million, is gaining attention for its IIoT solutions, notably partnering with HGlobal to enhance paramedic services using its BeMini 5G tracker. Despite a decline in net profit margin from 6% to 3.2%, the company remains financially stable with more cash than debt and well-covered liabilities. Its revenue from the Software & Programming segment reached CA$18.25 million, though earnings growth has been negative recently at -24%. The board and management are experienced, ensuring strategic oversight as they explore potential share buybacks to optimize capital structure. Take a closer look at BeWhere Holdings' potential here in our financial health report. Examine BeWhere Holdings' past performance report to understand how it has performed in prior years. enCore Energy Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: enCore Energy Corp. focuses on the acquisition, exploration, development, and extraction of uranium resource properties in the United States, with a market cap of CA$761.81 million. Operations: The company's revenue is primarily generated from the acquisition, exploration, and development of mineral properties, amounting to $46.18 million. Market Cap: CA$761.81M enCore Energy Corp., with a market cap of CA$761.81 million, is focused on uranium resource development in the U.S. Despite its unprofitable status and recent removal from several Russell Growth Benchmarks, the company shows operational progress at its Alta Mesa project, achieving record uranium extraction rates. The firm has a cash runway for less than a year based on current free cash flow but maintains more cash than debt and covers both short- and long-term liabilities with assets. Management changes aim to enhance operational efficiency as enCore advances wellfield expansion strategies in Texas projects. Navigate through the intricacies of enCore Energy with our comprehensive balance sheet health report here. Review our growth performance report to gain insights into enCore Energy's future. Lara Exploration Simply Wall St Financial Health Rating: ★★★★★★ Overview: Lara Exploration Ltd., with a market cap of CA$115.42 million, operates through its subsidiaries to acquire, explore, develop, and evaluate mineral properties in Brazil, Peru, and Chile. Operations: Lara Exploration Ltd. has not reported any specific revenue segments at this time. Market Cap: CA$115.42M Lara Exploration Ltd., with a market cap of CA$115.42 million, is pre-revenue and debt-free, focusing on mineral properties in South America. While the company remains unprofitable with losses increasing at 18.2% annually over five years, its short-term assets of CA$4.7 million comfortably cover liabilities of CA$114.9K. Lara's experienced board and management team provide stability amid financial challenges, and the firm has sufficient cash runway for over a year despite declining free cash flow trends. Recent earnings show reduced quarterly losses compared to last year, reflecting slight operational improvements without shareholder dilution concerns. Dive into the specifics of Lara Exploration here with our thorough balance sheet health report. Gain insights into Lara Exploration's past trends and performance with our report on the company's historical track record. Seize The Opportunity Click here to access our complete index of 454 TSX Penny Stocks. Interested In Other Possibilities? Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include TSXV:BEW TSXV:EU and TSXV:LRA. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting
International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

Yahoo

time7 hours ago

  • Yahoo

International Myeloma Society Accepts Telo Genomics' MRD Abstract for Presentation at Its 2025 Meeting

Toronto, Ontario--(Newsfile Corp. - July 24, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of telomeres, today announced that the International Myeloma Society ("IMS") has accepted Telo Genomics' abstract submission for a poster presentation on minimal residual disease ("MRD") during the upcoming 22nd International Myeloma Society Annual Meeting in Toronto, Canada. The new abstract titled, "3D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression," will be presented at the meeting by Dr. Yulia Shifrin, Laboratory Director of Telo Genomics and published in Clinical Lymphoma, Myeloma & Leukemia. The abstract entails a technical methodology of MRD assessment based on TeloView profiling. Details of the abstract will be provided after the poster session. TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide actionable information on risk of relapse to clinicians. The International Myeloma Society (IMS) is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its upcoming 22nd Annual Meeting, will take place from September 17-20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field. "We are excited to share the next clinical application of our 3D telomere application for MRD for multiple myeloma at IMS," said Dr. Sabine Mai, Telo's Co-Founder. "The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD." The Company announces that, further to its news release dated February 27, 2025, the Company has issued an aggregate of 411,539 common shares ("Shares") to Trusted Health Advisors LLC ("THA"), to compensate THA for its provision of services related to the partnering and commercialization of Telo's diagnostic technologies from January to July 1, 2025. Pursuant to the agreement between THA and the Company, 214,605 Shares were issued at a deemed price of $0.12 per Share, and 196,934 Shares were issued at a deemed price of $0.125 per Share, for total consideration of approximately $50,369, or US$36,000. All Shares are subject to a four-month hold period expiring November 11, 2025, in accordance with applicable securities law and TSX-V policies. In addition, the Shares issued at $0.12 per Share are subject to a voluntary resale restriction expiring March 31, 2026, and the Shares issued at $0.125 per Share are subject to a voluntary resale restriction expiring June 30, 2026. About MRD Assessment Minimal Residual Disease ("MRD") is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma. MRD testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second most common blood cancer with an incidence of 35,000 new cases every year in the US, and ~180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over 5 years, but MM is still considered incurable. Two asymptomatic precursors, Monoclonal Gammopathy of Unknown Significance ("MGUS") and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1% per year, SMM is more heterogenous with nearly 40% of patients progressing in the first 5 years, 15% in the next 5 years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. About Telo Genomics Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining our team's considerable expertise in quantitative analysis of 3D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of our proprietary technology have been substantiated in 160+ peer reviewed publications and in 30+ clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Our lead application, Telo-MM is being developed to provide important, actionable information to medical professionals in the treatment of Multiple Myeloma, a deadly form of blood cancer. For more information, please visit For further information, please contact:Guido BaechlerExecutive Chairman647-477-9365info@ Centre, South Tower101 College Street, Suite 200Toronto, ON, M5G Neither the TSX Venture Exchange nor its Regulation Services Provider (as such term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Note Regarding Forward-Looking Statements Certain information contained herein may constitute "forward-looking information" under Canadian securities legislation. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "will", or variations of such words and phrases or statements that certain actions, events or results "will" occur. Certain forward-looking statements, including statements regarding the Company's receipt of TSXV acceptance of the stock option grant are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information, including capital expenditures and other costs. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. The Company will not update any forward-looking statements or forward-looking information that are incorporated by reference herein, except as required by applicable securities laws. To view the source version of this press release, please visit

NowVertical to Attend Qlik AI Reality Tour, Deepening Strategic Partnerships and Showcasing AI Leadership
NowVertical to Attend Qlik AI Reality Tour, Deepening Strategic Partnerships and Showcasing AI Leadership

Hamilton Spectator

time7 hours ago

  • Hamilton Spectator

NowVertical to Attend Qlik AI Reality Tour, Deepening Strategic Partnerships and Showcasing AI Leadership

TORONTO, July 24, 2025 (GLOBE NEWSWIRE) — NowVertical Group Inc. (TSXV: NOW) ('NowVertical' or the 'Company'), a leading data and AI solutions provider, is pleased to announce its participation in the Qlik AI Reality Tour event in São Paulo, Brazil on July 29, 2025. This event brings together Qlik's most innovative partners, clients, and thought leaders to explore the evolving landscape of enterprise AI adoption. This attendance follows NowVertical's recent recognition as Qlik's 2024 Latin America Channel Growth Partner of the Year , and reflects the Company's expanding global footprint and commitment to accelerating value through strategic technology partnerships. As part of the event, NowVertical will also present the transformational success of Natural One, a leading 100% natural juice company. The case study demonstrates how through partnering with NowVertical and Qlik, Natural One restructured its data architecture and modernised its sales, HR, and operational processes—embedding data culture across the organisation and driving tangible improvements in performance, efficiency, and decision-making. The Qlik AI Reality Tour provides an opportunity for NowVertical to engage directly with enterprise customers, exchange insights with ecosystem peers, and contribute to shaping the future of real-world AI implementation. Events like this showcase the Company's ability to deliver measurable results through collaborative innovation and real-world application of data intelligence. 'As enterprises around the world look to operationalise AI at scale, the opportunity lies in pairing vision with execution,' said Sandeep Mendiratta, CEO of NowVertical. 'NowVertical is uniquely positioned to help organisations make AI real—translating strategy into true business. Events like this deepen our ability to deliver on that promise through strong partner collaboration.' NowVertical's attendance underscores its position as a trusted transformation partner, uniquely equipped to deliver scalable, AI-powered data solutions across complex enterprise environments. With recognised expertise in integrating cloud, analytics, and business intelligence platforms, NowVertical continues to unlock measurable value for clients navigating digital modernisation. For more information about the Qlik AI Reality Tour, visit: About NowVertical Group Inc. NowVertical is a global data and analytics company which helps clients transform data into tangible business value with AI, fast. Offering a comprehensive suite of solutions and services, the Company enables clients to quickly harness the full potential of their data, driving measurable outcomes and accelerating potential return on investment. Enterprises optimize decision-making, improve operational efficiency, and unlock long-term value from their data using the Company's AI-Infused first party and third-party technologies. NowVertical is growing organically and through strategic acquisitions. For further details about NowVertical, please visit . Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. For further information, please contact: Andre Garber, CDO IR@ Investor Relations: Bristol Capital Ltd. Stefan Eftychiou stefan@ +1(905)326-1888 x60‍ Forward-Looking Statements This news release contains forward-looking information and forward-looking information within the meaning of applicable Canadian securities laws (together 'forward-looking statements'), including, with respect to the availability of funds under the Facilities, the ability of NowVertical to utilize funds under the Facilities, the effect of the Facilities on NowVertical's operations contemplated in this press release on NowVertical's business, finances and operations. Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable by management, are inherently subject to significant business, economic and competitive uncertainties, and contingencies, certain of which are unknown. Forward-looking statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'will', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause future results, performance, or achievements to be materially different from the estimated future results, performance or achievements expressed or implied by the forward-looking statements and the forward-looking statements are not guarantees of future performance. Forward-looking statements are qualified in their entirety by inherent risks and uncertainties, including: adverse market conditions; risks inherent in the data analytics and artificial intelligence sectors in general; regulatory and legislative changes; that future results may vary from historical results; inability to service the Company's debt; any inability to realize the expected benefits and synergies of acquisitions or dispositions; that market competition may affect the business, results and financial condition of the Company and other risk factors identified in documents filed by the Company under its profile at , including the Company's management's discussion and analysis for the year ended December 31, 2024. Further, these forward-looking statements are made as of the date of this news release and, except as expressly required by applicable law, the Company assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store